The DOI matches its Crossref record.
Increased levels of KL‐6 and subsequent mortality in patients with interstitial lung diseases
Open accessAbstract
Abstracts.: Objectives. KL‐6 is a specific marker in patients with interstitial lung diseases (ILDs); however, the relationship between elevated levels of KL‐6 and subsequent mortality is not well defined. To determine if elevated serum levels of KL‐6 are associated with increased mortality, and to identify the most suitable cut‐off level of KL‐6 by which to distinguish between good prognosis and poor prognosis, we evaluated the prognostic significance of serum KL‐6 levels in patients with stable‐state ILDs. Methods. Two hundred and nineteen patients diagnosed with ILDs (152 with idiopathic interstitial pneumonia and 67 with collagen disease‐associated pulmonary fibrosis) at Tsukuba University Hospital from April 1999 to October 2005 were entered in this study. Serum KL‐6 levels in patients with ILDs were measured with a commercially available enzyme immunoassay kit, and these patients were then followed up. Results. During the follow‐up period, 58 of the 219 patients died of respiratory failure. Patients who died during this period had higher levels of KL‐6 than did those who did not (P = 0.0004). The receiver operating characteristic curve analysis showed 1000 U mL−1 as the most suitable cut‐off level by which to distinguish between the two groups of patients. The 95% specificity serum KL‐6 level with poor outcome was 2750 U mL−1. In univariate and multivariate analysis, elevated serum KL‐6 (>1000 U mL−1) in the stable state indicated poor prognosis (P = 0.0005, log‐rank test; P = 0.0001, Cox proportional hazard model). Conclusions. Elevated KL‐6 level may provide simple, yet valuable information by which to identify patients with ILDs who are at increased risk for subsequent mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases
Ishikawa, N., Hattori, N., Yokoyama, A., & Kohno, N. (2012) · Respiratory Investigation · doi:10.1016/j.resinv.2012.02.001 · Cited by 402
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Guiot, J., Moermans, C., Henket, M., Corhay, J.-L., & Louis, R. (2017) · Lung · doi:10.1007/s00408-017-9993-5 · Cited by 147
Metadata
- Authors
- SATOH, H., KURISHIMA, K., ISHIKAWA, H., & OHTSUKA, M.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2006-09-25
- Volume
- 260
- Issue
- 5
- Pages
- 429-434
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W1976954029
- Cited by
- 171
- References
- 0
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased levels of KL‐6 and subsequent mortality in patients with interstitial lung diseases. https://app.cochat.ai/papers/10.1111/j.1365-2796.2006.01704.x
- The paper
- SATOH, H., KURISHIMA, K., ISHIKAWA, H., & OHTSUKA, M. (2006). Increased levels of KL‐6 and subsequent mortality in patients with interstitial lung diseases. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2006.01704.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.